Singapore, Feb. 17 -- Galux, a South Korea-based biotech startup pioneering artificial intelligence (AI)-driven protein therapeutics design, has announced the successful completion of a $29 million (KRW 42 billion) Series B financing. With this round, the company's total capital raised reaches $47 million (KRW 68 billion).

The Series B round brought together a group of long-term supporters and new institutional backers. InterVest, DAYLI Partners, and PATHWAY Investment participated as existing investors, alongside new investors including Yuanta Investment, Korea Development Bank (KDB), SL Investment, NCORE Ventures, SneakPeek Investments, Korea Investment & Securities, and Mirae Asset Securities.

Galux previously closed an $18 million (...